Medical Management of Bladder Cancer

Gary R. MacVicar; Timothy M. Kuzel

doi:10.1002/9781118589199.ch96

Medical Management of Bladder Cancer

Gary R. MacVicar^*, Timothy M. Kuzel

^*Corresponding author for this work

Dermatology

Research output: Chapter in Book/Report/Conference proceeding › Chapter

Abstract

This chapter presents a series of case studies with questions and answers on the medical management of bladder cancer. It commences with a discourse regarding a lymph node dissection. A lymph node dissection is also undertaken in all patients, and a urinary diversion, typically an ileal conduit or orthotopic neobladder, is created. However, several reports suggest that an extended lymph node dissection improves survival relative to a limited lymph node dissection, regardless of nodal status. The chapter focuses on the outcomes in metastatic bladder cancer patients. Molecular prognostic factors are also being developed based on translational study of bladder cancer specimens and preclinical models.

Original language	English (US)
Title of host publication	Cancer Consult
Subtitle of host publication	Expertise for Clinical Practice
Publisher	Wiley-Blackwell
Pages	628-633
Number of pages	6
ISBN (Electronic)	9781118589199
ISBN (Print)	9781118589212
DOIs	https://doi.org/10.1002/9781118589199.ch96
State	Published - Jun 20 2014

Keywords

Bladder cancer
Lymph node dissection

ASJC Scopus subject areas

General Medicine

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1002/9781118589199.ch96

Cite this

@inbook{28330fc5e67f4d40a8fbe85f5341db0a,

title = "Medical Management of Bladder Cancer",

abstract = "This chapter presents a series of case studies with questions and answers on the medical management of bladder cancer. It commences with a discourse regarding a lymph node dissection. A lymph node dissection is also undertaken in all patients, and a urinary diversion, typically an ileal conduit or orthotopic neobladder, is created. However, several reports suggest that an extended lymph node dissection improves survival relative to a limited lymph node dissection, regardless of nodal status. The chapter focuses on the outcomes in metastatic bladder cancer patients. Molecular prognostic factors are also being developed based on translational study of bladder cancer specimens and preclinical models.",

keywords = "Bladder cancer, Lymph node dissection",

author = "MacVicar, {Gary R.} and Kuzel, {Timothy M.}",

note = "Publisher Copyright: {\textcopyright} 2014 John Wiley and Sons, Inc.",

year = "2014",

month = jun,

day = "20",

doi = "10.1002/9781118589199.ch96",

language = "English (US)",

isbn = "9781118589212",

pages = "628--633",

booktitle = "Cancer Consult",

publisher = "Wiley-Blackwell",

}

TY - CHAP

T1 - Medical Management of Bladder Cancer

AU - MacVicar, Gary R.

AU - Kuzel, Timothy M.

PY - 2014/6/20

Y1 - 2014/6/20

N2 - This chapter presents a series of case studies with questions and answers on the medical management of bladder cancer. It commences with a discourse regarding a lymph node dissection. A lymph node dissection is also undertaken in all patients, and a urinary diversion, typically an ileal conduit or orthotopic neobladder, is created. However, several reports suggest that an extended lymph node dissection improves survival relative to a limited lymph node dissection, regardless of nodal status. The chapter focuses on the outcomes in metastatic bladder cancer patients. Molecular prognostic factors are also being developed based on translational study of bladder cancer specimens and preclinical models.

AB - This chapter presents a series of case studies with questions and answers on the medical management of bladder cancer. It commences with a discourse regarding a lymph node dissection. A lymph node dissection is also undertaken in all patients, and a urinary diversion, typically an ileal conduit or orthotopic neobladder, is created. However, several reports suggest that an extended lymph node dissection improves survival relative to a limited lymph node dissection, regardless of nodal status. The chapter focuses on the outcomes in metastatic bladder cancer patients. Molecular prognostic factors are also being developed based on translational study of bladder cancer specimens and preclinical models.

KW - Bladder cancer

KW - Lymph node dissection

UR - http://www.scopus.com/inward/record.url?scp=84946429465&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84946429465&partnerID=8YFLogxK

U2 - 10.1002/9781118589199.ch96

DO - 10.1002/9781118589199.ch96

M3 - Chapter

AN - SCOPUS:84946429465

SN - 9781118589212

SP - 628

EP - 633

BT - Cancer Consult

PB - Wiley-Blackwell

ER -

Medical Management of Bladder Cancer

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this